Mirdametinib
- Generic Name
- Mirdametinib
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3IN2O4
- CAS Number
- 391210-10-9
- Unique Ingredient Identifier
- 86K0J5AK6M
- Background
PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
- Conditions
- Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT06876142
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
- Conditions
- Well Differentiated LiposarcomaDedifferentiated LiposarcomaLiposarcomaMyxoid LiposarcomaRound Cell LiposarcomaMyxoid Pleomorphic LiposarcomaPleomorphic LiposarcomaUnresectable LiposarcomaUnresectable Dedifferentiated Liposarcoma
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06843967
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
- Conditions
- Primary Malignant Peripheral Nerve Sheath Tumors
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 8
- Registration Number
- NCT06693284
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- C17 Council
- Target Recruit Count
- 50
- Registration Number
- NCT06666348
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 24
- Registration Number
- NCT06159166
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Mirdametinib in Histiocytic Disorders
- Conditions
- Rosai-Dorfman Disease (RDD)Histiocytic DisordersLangerhans Cell Histiocytosis (LCH)Juvenile Xanthogranuloma (JXG)
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 40
- Registration Number
- NCT06153173
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
- Conditions
- Venous MalformationSlow-Flow Vascular MalformationFast-Flow Vascular MalformationArteriovenous MalformationsPIK3CA-related Overgrowth SpectrumLymphatic Malformation, Low FlowLymphatic MalformationVascular AnomalyKRAS G12DVascular Malformations
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05983159
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺The Royal Children's Hospital, Parkville, Victoria, Australia
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 24
- Registration Number
- NCT05937906
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, Burgundy, France
Mirdametinib + BGB-3245 in Advanced Solid Tumors
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05580770
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Yale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
- Conditions
- Breast CancerHER2-negative Breast CancerMEK1 Gene MutationMetastatic Breast CancerBreast Cancer Stage IVMEK2 Gene MutationSolid Carcinoma
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT05054374
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.